Hipofosfatasia: perspectiva preclínica de su fisiopatología y tratamiento
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Hypophosphatasia (HPP) is a genetic disorder caused by loss-of-function mutations in the ALPL gene, which encodes tissue-nonspecific alkaline phosphatase (TNAP), an enzyme essential for physiological skeletal and dental mineralization. Disease severity ranges from life-threatening perinatal and infantile forms to milder late-onset forms manifesting in adulthood or affecting only dentition. Enzyme replacement therapy based on recombinant mineral-targeted alkaline phosphatase (asfotase alfa) has been approved for the treatment of pediatric-onset HPP and has significantly improved survival and skeletal outcomes. This narrative review summarizes the pathophysiology of hypophosphatasia and discusses advances in preclinical research, including gene therapy approaches, small-molecule inhibitors, and cell-based therapeutic strategies evaluated in experimental models.
Fields of Study & Subjects
Alkaline Phosphatase Research Studies
Parathyroid Disorders and Treatments
Bone and Dental Protein Studies
Publication details
- Journal / source
- EndoAr
- Volume
- 2
- Issue
- 1
- Pages
- 52–68
- Publication date
- 10 March 2026
- Language
- EN